INTERNATIONAL BIOTECHNOLOGY TRUST PLC (the Company)
Portfolio Update as at 31 January 2018
Net Assets |
£233m |
Net Assets per share |
619p |
Share price |
614p |
Total value of unquoted investments |
£20m |
Total number of portfolio companies |
92 |
Dividend |
4% of NAV per annum |
Top Ten Quoted Investments
Company Name |
% NAV |
Biogen |
6.2 |
Celgene |
4.6 |
Nektar |
4.4 |
Regeneron |
4.0 |
Exelixis |
3.8 |
Acadia |
3.7 |
Vertex |
3.6 |
Adamas |
3.6 |
Genmab |
3.1 |
Gilead |
3.1 |
|
----------- |
Total |
40.1 |
Geographical Allocation |
% NAV |
US & Canada |
91 |
Europe & UK |
9 |
|
----------- |
Total |
100 |
Quoted/Unquoted Allocation |
% NAV |
Quoted |
92 |
Unquoted |
8 |
|
----------- |
Total |
100 |
NAV % Market Cap |
% NAV |
Large Cap >USD10BN |
40 |
Mid Cap =USD1-10BN |
34 |
Small Cap <USD1BN |
26 |
|
----------- |
Total |
100 |
NAV % by Therapeutic Areas |
% NAV |
Oncology |
38 |
Rare diseases |
14 |
CNS |
14 |
Inflammation |
8 |
Ophthalmology |
6 |
Metabolic |
5 |
Infectious Diseases |
4 |
Medtech |
2 |
Other |
9 |
|
----------- |
Total |
100 |
BNP Paribas Secretarial Services Limited
Company Secretary
21 FEBRUARY 2018